NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 2Nd September, 2022
Outcome of the Board Meeting held on 2nd September, 202202-09-2022
NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 2Nd September, 2022
Outcome of the Board Meeting held on 2nd September, 2022Natco Pharma scouting for buys to boost domestic biz
Natco Pharma The Hyderabad-based company is interested in an entity with a revenue of 100 to 200 croreNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call Transcript for the Q1 FY22-23NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO announces tentative approval to its ANDA for Trabectedin (generic for Yondelis(r))Hold Natco Pharma: target of Rs 735: ICICI Direct
ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 735 in its research report dated August 13, 2022.NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Natco Pharma Limited has informed the Exchange about Newspaper Advertisements for Intimation of Record DateResults Earnings Call for Q1FY23 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
weblink for the Audio Transcript for the Earnings call held on 10th August, 2022NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended 30th June, 2022NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication for unaudited financial results for the quarter ended 30th June, 2022